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ABSTRACT The "membrane bilayer" pathway (Rhodes, D. G., J. G. Sarmiento, and L. G. Herbette. 1985. Mol. Pharmacol.
27:612-623.) for 1,4-dihydropyridine calcium channel drug (DHP) binding to receptor sites in cardiac sarcolemmal membranes
has been extended to include the interaction of amphiphiles within the lipid bilayer. These studies focused on the ability of the Class
IlI antiarrhythmic agents bretylium and clofilium to nonspecifically inhibit DHP-receptor binding in canine cardiac sarcolemma.
Clofilium was found to inhibit nimodipine binding with an inhibition constant of 5 ,uM, whereas bretylium had no effect on
nimodipine binding. Small angle x-ray diffraction was then used to examine the differential ability of these two Class III agents to
inhibit DHP-receptor binding. The time-averaged locations of bretylium, clofilium, and nimodipine in bovine cardiac
phosphatidylcholine (BCPC) bilayers (supplemented with 13 mol% cholesterol) were determined to a resolution of 9 A. The location
of bretylium as dominated by its phenyl ring in BCPC bilayers was found to be at the hydrocarbon core/water interface, similar to
that of the dihydropyridine ring of nimodipine. The location of clofilium as dominated by its phenyl ring was found to be below the
hydrocarbon/core water interface within the hydrocarbon chain region of the bilayer, similar to that of the phenyl ring of nimodipine.
The location of the dihydropyridine ring portion of nimodipine has previously been shown by neutron diffraction to be located at the
hydrocarbon core/water interface of native sarcoplasmic reticulum, consistent with the small angle x-ray data from model
membranes in this paper. Therefore, we speculate that the nonspecific inhibition arises from the interaction of clofilium's phenyl
ring with the site on the calcium channel receptor where the phenyl ring portion of nimodipine must interact. The DHP-receptor
binding pathway would then involve both nonspecific (membrane) and specific (protein) binding components, both of which are
necessary for receptor binding.
INTRODUCTION
1,4-dihydropyridine calcium channel agonists and antag-
onists (DHPs) are a class of similar chemicals that
reversibly modulate cardiac and smooth muscle excita-
tion-contraction coupling mechanisms (for review see
Janis et al., 1987). Despite the important clinical role of
DHPs, the mechanistic basis for their action on cellular
calcium flux has yet to be fully characterized. Since the
recent review of this subject (Mason et al., 1990), our
understanding of the DHP-receptor binding pathway
has been refined and extended, principally through
studies of the interactions of cardiac drugs with biologi-
cal membranes.
DHPs inhibit voltage-sensitive calcium channels in
cardiac sarcolemma in a highly stereoselective, saturable
and reversible manner (Belleman et al., 1983). Equilib-
rium dissociation constants for the interaction of DHPs
with receptors in cardiac, smooth and skeletal muscle
are in the range of 0.1 to 5 nM. These molecules are also
generally lipophilic and partition nonspecifically with
relatively high partition coefficients into model and
native membranes (Herbette et al., 1986). This lipophilic-
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ity often correlates with electrophysiological effects
(Kokubun and Reuter, 1984), suggesting that this prop-
erty is directly involved in its mechanism of action.
These and other observations have led to the formula-
tion of a "membrane bilayer pathway" describing the
mechanism of DHP-receptor binding (Rhodes et al.,
1985). A general hydrophobic pathway has also been
proposed to address receptor binding for other am-
phiphilic drugs, such as local anesthetics (Hille, 1977),
general anesthetics (for review see Franks and Lieb,
1987), barbituates (Miller and Roth, 1986), benzodiaz-
epines (for review see Herbette et al., 1991), canna-
binoids (for review see Martin, 1986), and others. The
membrane bilayer pathway of Rhodes et al. (1985)
involves drug partitioning to an energy favorable loca-
tion in the bilayer followed by lateral diffusion to its
protein receptor site. A substantial kinetic advantage is
gained by the bilayer pathway (versus a diffusion-limited
aqueous approach) in biological membranes where the
receptor site density is low (McCloskey and Poo, 1986)
and for DHPs with high partition coefficients for the
membrane bilayer (Herbette et al., 1986). Experimental
support for this pathway exists in the form of studies of
the lateral diffusion of DHPs in membranes (Chester et
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al., 1987), receptor binding studies (Affolter and Coro-
nado, 1985; Valdivia and Coronado, 1988), and electro-
physiological studies (Kokubun and Reuter, 1984). The
proposed membrane bilayer pathway model links nonspe-
cific DHP-membrane interactions, as described above,
with specific binding to a stereoselective, saturable and
reversible high affinity protein receptor site.
To further investigate interactions of DHPs with both
the membrane bilayer and their target protein receptor,
we have recently examined the ability of other lipid
soluble drugs to inhibit the binding of nimodipine to its
high affinity receptor site. Bretylium is a Class III
antiarrhythmic drug which is potentially useful in termi-
nating abnormal cardiac rhythms (Steinberg, 1988). A
diverse group of compounds possess Class III activity
including bretylium, clofilium and amiodarone, which
share the property of being amphiphilic molecules
containing halogenated phenyl moieties. Proposed ionic
mechanisms for Class III activity include effects on
inward sodium currents, calcium influx, and outward
potassium currents, although at least for amiodarone a
specific receptor is not believed to exist. In this study, the
molecular basis for the differential ability of bretylium
and clofilium to inhibit DHP-receptor binding in canine
cardiac sarcolemmal membranes was addressed. Small
angle x-ray diffraction was used to determine the time-
averaged location of the Class III antiarrhythmic agents
clofilium and bretylium (in addition to that of nimo-
dipine) in the membrane bilayer and these locations
were compared with the ability of these agents to
nonspecifically inhibit nimodipine's binding to its recep-
tor.
METHODS AND MATERIALS
Chemicals
Bretylium was a gift from American Hospital Supply Corp. (McGaw
Park, IL). Clofilium was a gift of Eli Lily and Co. (Indianapolis, IN).
Nimodipine was a gift of Miles Pharmaceuticals, a Division of Miles
Laboratories (West Haven, CT). The drugs were dissolved in 100%
ethanol due to their limited aqueous solubility, and stored at 0°C.
Bovine cardiac phosphatidylcholine (BCPC) was purchased from
Avanti Polar-Lipid, Inc. (Birmingham, AL), and stored in powdered
form at 0°C. Lipid purity and integrity was assessed, before and after
x-ray diffraction studies, to be >95% phosphatidylcholine by thin-
layer chromatography. All other chemicals were reagent grade and all
solutions were made using glass distilled deionized water.
Competition binding analysis
Crude canine cardiac sarcolemmal (CSL) membranes were isolated by
the method of Jones et al. (1980).
150 nM 3H-nimodipine and varying concentrations of either bretylium
or clofilium were incubated with 150 p,g of CSL membranes in a final
volume of 495 pLl, at 25°C for 90 min. The reaction mixtures were then
rapidly filtered through GF-C filters pretreated with 0.3% polyethylen-
imine, and washed with four volumes (2.5 ml) of buffer (50 mM
Tris-HCl, pH 7.4). The radioactivity remaining in the membranes on
the filters was then determined by scintillation counting.
The bretylium and clofilium concentration range used for the
competition binding assays was 3 nM to 500 p.M. Control experiments
were performed competing nonradiolabeled nimodipine against 3H-
nimodipine. These experiments utilized fixed concentrations of 150
nM 3H-nimodipine against varying concentrations of nimodipine,
ranging from 0.05 to 300 nM. Nonspecific binding was determined by
competing 150 nM 3H-nimodipine against saturating concentrations
(50 ,uM) of nimodipine. All competition binding values were corrected
for nonspecific binding.
The values were expressed as percent of total counts per minute.
Total cpms were determined by counting CSL membranes in the
presence of 150 nM 3H-nimodipine and no drug. Three data points
were determined for each concentration (n = 3). Inhibition constants
(Ks) were determined as the concentration of drug necessary for
half-maximal inhibition of 3H-nimodipine binding.
Preparation of multibilayer samples
for x-ray diffraction
The phospholipid composition of the CSL membranes was previously
determined to be primarily phosphatidylcholine (45%) and phosphati-
dylethanolamine (36%) with lesser amounts of phosphatidylserine and
sphingomyelin (8%), phosphatidylinositol (7%), and phosphatidylglyc-
erol (1%); cholesterol accounted for - 13 mol% of the phospholipid
content (Mason et al., 1989). As a model system, we used a source of
BCPC supplemented with 13 mol% cholesterol.
BCPC multilamellar lipid vesicles were prepared in the absence or
presence of known amounts of bretylium, clofilium, or nimodipine
essentially by the method of Bangham et al. (1965). BCPC multilamel-
lar vesicles were prepared as follows: the desired amount of lipid and
the desired amount of cholesterol dissolved in CHCl3 were placed in a
glass test tube and dried down to a thin film under vacuum. Buffer (0.5
mM Hepes, 2.0 mM NaCl, pH 7.27), in the presence and absence of
known bretylium, clofilium, or nimodipine concentrations, was added
to yield a final lipid concentration of 5 mg/ml and a drug-to-lipid ratio
of 1:30. This solution was then vortexed and sonicated to form a cloudy
white suspension of multilamellar vesicles. The imembrane samples
were stored at 40C.
Multibilayer samples for small angle x-ray diffraction were prepared
as described previously (Chester et al., 1987). Sample preparation and
dehydration took -3 h; this ensures sufficient time, based on our
kinetic measurements, for drug partitioning into the membrane to
reach equilibrium.
The salts used for controlling relative humidity (r.h.) were LiCl,
13%; MgCl2, 34%; K2CO3, 45%; Mg(NO3)2, 55%; NaNO3, 66%;
K2tartarate, 72%; (NH4)2SO4, 81%; Na/Ktartarate, 87%; and ZnSO4,
93%.
Small angle x-ray diffraction
CuK x-rays produced by a GX-18 rotating anode generator (Enraf
Nonius, Bohemia, NY) were either line focused for the small angle
studies or point focused for the equatorial studies using Franks' mirror
assemblies. A nickel filter was used to select CuKrx radiation (X = 1.54
A).
Diffraction data collection
Data was recorded on a Braun position sensitive 1-dimensional
detector (Innovative Technologies, Inc., South Hamilton, MA) inter-
faced to a MicroVax II (Digital Equip. Corp., Maynard, MA).
Data reduction (background and geometrical corrections) has been
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described previously (Herbette et al., 1985). Briefly, an exponential
function was fit to the background and subtracted in the integration
routine. Since the entire lamellar reflection for each observed intensity
was collected by the detector, the lamellar intensity functions from the
BCPC samples collected with the electronic detector were simply
Lorentz corrected by a factor of s = 2 sin 0iA.
Data were recorded on Kodak DEF-5 (Eastman Kodak Co., Roches-
ter, NY) film and qualitatively examined to determine the high angle
acyl-chain packing of the samples and to verify the low angle detector
data.
Phasing the data
A swelling analysis was used to phase the lamellar reflections for each
experiment (Moody, 1963). Eight sets of intensity data obtained at
different hydration states ranging from 93 to 13% r.h., each with
unique unit cell repeat distances, were used to assign an unambiguous
phase combination to the experimentally obtained structure factors
(h = 1-4). Due to insufficient data, the shape of the structure factor
function in the region ofh = 5 and h = 6 could not be ascertained. The
possible phase combinations were further refined to a single solution
using the "swellcheck" analysis described below. This phase combina-
tion was confirmed through the autocorrelation analysis. The final
phase choice was the only physically reasonable combination, in terms
of empirical examination of resultant electron density profiles.
Swellcheck analysis
The swelling series utilized in the experiments ranged from 93 to 13%
r.h. The electron density profile at each humidity was calculated as the
symmetric Fourier transform of the square root of the Lorentz-
corrected, integrated intensity function along with the corresponding
phase information. The resultant electron density profiles were inverse
Fourier transformed to obtain the continuous structure factor func-
tion, F(s), at each hydration state. The resultant structure factors were
sampled at integer multiples of the reciprocal unit cell repeat
distances, 1Id, obtained for the entire swelling series and then Fourier
transformed to reconstruct the experimental electron density profiles,
p(x) (Shannon, 1949; Sayre, 1953). The reconstructed electron density
profiles, Pr(X), corresponding to the repeat distance at each humidity,
were compared to the corresponding experimental electron density
profiles, Pex(x). Assuming the structure is conserved at the hydration
states used to construct the structure factor, then pr(X) for a given
repeat distance should be identical to, within experimental error, the
Pex(X) at that same relative humidity. This analysis tests the validity of
the assumption used in the swelling analysis. The swellcheck analysis
also provides a quantitative error analysis, presented in the form of a
calculated residual (as described below). The errors reflected in this
residual include experimental error in sample variation and data
collection, deviation of the sample from the assumption of the swelling
analysis, and error in the data analysis.
Demanding consistency in the swellcheck analysis aided in unambig-
uously verifying the phase combination chosen for the structure factors
and in eliminating the remaining ambiguous phase combinations.
Autocorrelation analysis
The multilayer autocorrelation function, PmI(x), was calculated as the
Fourier transformation of the corrected intensities placed at the
corresponding hId values. A difference-PmI(x), APml(x), was calculated
as the normalized drug-Pml(x), PdmI(x), minus the normalized control-
PmI(x), Pc,,,1(x). Assuming the isomorphic addition of the drug to the
membrane bilayer, the difference-autocorrelation function can be
interpreted to directly yield the position of the drug molecule in the
membrane. Details of this method can be found in the Appendix.
RESULTS
The structural formulas of the Class III antiarrhythmic
agents bretylium and clofilium and the DHP nimodipine
are shown in Fig. 1.
Competition binding analysis
Bretylium, in the concentration range of 3 nM to 500
p,M, did not inhibit nimodipine binding to the DHP
receptor in crude CSL membranes. At 500 ,uM bretylium
competing against 150 nM 3H-nimodipine, 100% of the
radiolabeled DHP remains bound to its high affinity
receptor site (n = 3). Clofilium, however, displaces 90%
of the 3H-nimodipine at a concentration of 150 p,M (Fig.
2). Another Class III antiarrhythmic agent, amiodarone,
gave a similar inhibition effect as that observed with
clofilium (data not shown).
The Ki value for clofilium is 5 p,M, whereas bretylium
does not inhibit nimodipine binding to CSL membranes.
The Ki value determined for nimodipine competed
against itself is 0.5 nM.
Small angle x-ray diffraction studies
The swelling series ranged from 93 to 13% r.h. for both
drug-containing and control BCPC samples. The unique
phase combination proved to be correct for the following
reasons: (a) a F(s) with an unreasonable phase combina-
CH3
( CH 2- N* C2H 5
BfCH3Br e Cm
Bretyllum
CSNHCI.
Cl CH2(CH2)3NN(CHg)CH3
Clofillum
H
H3C N CH3
(CH3)2CHOC COCH2CH20CH3
NO2
Nimodipine
FIGURE 1 The structural formulas for the three drugs used in these
studies. Bretylium and clofilium are Class III antiarrhythmic agents
which appear to possess similar mechanisms of action. The 1,4-
dihydropyridine, nimodipine, is a calcium channel antagonist possess-
ing binding affinity specific for the L-type calcium channel receptor of
cardiac sarcolemmal membranes.
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FIGURE 2 Nonspecific inhibition of nimodipine binding by bretylium
(filled squares), clofilium (open squares), and nimodipine (triangles).
150 nM of 3H-nimodipine is competed against varying concentrations
of bretylium, clofilium or nimodipine, for binding to receptor sites in
crude canine cardiac sarcolemmal membranes. The displacement of
radiolabeled nimodipine from the membranes reflects inhibition by
the competing compound and is calculated as the percent of total
counts per minute remaining in the membranes. The Ki value is
calculated as the concentration of drug necessary for half-maximal
inhibition of nimodipine binding.
tion failed to reconstruct the Pex(X) in the swellcheck
analysis, when sampled at the appropriate d-space and
Fourier transformed; (b) the APmI(x), which is phase
independent1, must be consistent with the experimental
difference-electron density profile, Ap(x).
Equatorial diffraction was examined to address the
possibility of major structural changes caused by the
presence of drug at a 1:30 drug-to-lipid ratio. Acyl-chain
packing, indicated by a single, very broad reflection at
1/4.7 A-', for both control and drug-containing samples,
was found not to be significantly different.
Membrane multibilayers prepared in the presence
and absence of bretylium, clofilium, or nimodipine gave
clearly defined, reproducible diffraction patterns. The
highest resolution diffraction patterns were obtained at
a bilayer hydration of 55% and temperatures of 5-10°C.
At 55% r.h. and 6°C, for example, we observed six sharp
lamellar diffraction orders with an average unit cell
repeat distance, d, of 57 A for a resolution 9 A (Fig. 3
and Table 1).
The bretylium-containing BCPC sample and its
matched control at 55% r.h. had similar repeat distances
of 59.0 and 59.2 A, respectively. The clofilium-con-
'Since we calculated the control or drug-containing Pml(x) using the
sampling theorem, our APnl (x) is not truly phase independent.
However, because our d-spaces differed by <0.5 A in all cases,
deviations in the structure factor modulus at the sampled d-spaces are
within our 5.1% experimental error.
FIGURE 3 X-ray diffraction patterns from BCPC multibilayers in the
(a) absence and (b) presence of bretylium at 55% relative humidity
and 6°C collected on a one-dimensional position sensitive x-ray
detector. Six sharp lamellar diffraction orders were observed which
index at reciprocal vectors of 1/59.2 A-i and 1/59.0 A-, respectively.
These diffraction patterns are representative of the type of diffraction
data observed in the described experiments.
taining sample and its matched control had similar
repeat distances of 54.5 and 55.0 A, respectively. The
nimodipine-containing sample and its matched control
had repeat distances of 55.9 and 56.3 A, respectively. In
each case, reproducible and localized differences were
observed between control and drug-containing samples,
which were attributed to the presence of drug. Each
drug-containing multibilayer and its matched control is a
representative sample selected from at least four identi-
cal multilayers, where all the samples in a series had the
same lyotropic history. The lyotropic progression for
each series was optimized for diffraction quality for the
drug-containing samples. Because different lyotropic
progressions gave optimal diffraction for the different
drug-containing samples, the lyotropic history, and sub-
sequently F(h) for the controls are not the same. The
BCPC lipids, in our hands, were found to be very
sensitive to the lyotropic progression.
All calculated electron density profiles exhibit charac-
teristics of phospholipid membrane bilayers. A relatively
Young et at.
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TABLE 1 Structure factors evaluated at hId for BPC In the
presence and absence of drug molecules
h F(h)cOntro F(h)clofilium
1 -0.9399 -0.9473
2 -0.0700 -0.0622
3 +0.1350 +0.1094
4 -0.2934 -0.2766
5 +0.0636 +0.0702
6 -0.0577 -0.0726
d = 55.OA d = 54.5A
h F(h)control F(h)nimodipine
1 -0.8312 -0.8480
2 -0.2772 -0.2768
3 +0.2818 +0.2623
4 -0.3906 -0.3672
5 +0.0124 +0.0055
6 -0.0053 -0.0244
d = 56.3A d = 55.9 A
h F(h)controj F(h)bretylium
1 -0.9087 -0.9069
2 -0.0402 -0.0586
3 +0.0945 +0.1232
4 -0.3651 -0.3719
5 +0.1262 +0.0948
6 -0.1199 -0.1080
d = 59.2A d = 59.oA
The average experimental error was determined to be 5.1% from the
swellcheck analysis.
electron deficient methyl trough is observed at 0 A, an
electron dense headgroup region is observed at + 22 A,
an acyl chain region is observed between 18 Al and 118
Al, and a water-space is observed at +d/2.
In the swellcheck analysis, the pr(X)s were compared
to the experimental profiles of the BCPC multibilayer
controls at 55% r.h. The deviation of the pr(X) from the
pex(x) represents the experimental error inherent in the
electron density profiles. Residuals were calculated, for
the reconstruction of the PeX(X)S, as
R = 7[ l Pex(X) - Pr(X) I / Pex(X)lI.
The average residual for the swellcheck reconstruction
was evaluated to be R = 0.051 for lxl < d/2. This
indicates a cumulative error of 5.1% inherent in the
p(x)s, which is consistent with previous error analyses
performed in our laboratory (Mason et al., 1989).
In the presence of clofilium, an increase in electron
density centered at + 13 A from the hydrocarbon core
center was observed with a distribution of 9 A < Ix <
16 A (Fig. 4 a). In the presence of nimodipine, an
increase in electron density centered at + 16 A from the
hydrocarbon core center was observed, with a distribu-
tion of 9 A < IxI < 22 A (Fig. 4 b). In the presence of
bretylium, an increase in electron density was observed
centered at 19 A from the hydrocarbon core center,
superimposing on the phospholipid headgroup/glycerol
backbone region of the BCPC bilayer, with a distribution
ranging from 14 A < ixl < 23 A (Fig. 4 c). It is
interesting that the extent of electron density distribu-
tion changes for nimodipine-containing samples com-
pletely overlaps the distributions of bretylium and clo-
filium, whereas the distributions of bretylium and
clofilium do not overlap. The possible implications of
this result will be considered in the discussion.
To evaluate the significance of a feature or perturba-
tion in the drug-containing p(x), a "degree of signifi-
cance,"
S = I Pd(X) Pc(X) I / I Pd(X) I ,
was calculated for drug-containing, pd(X), and control,
pc(x), electron density profiles. For the bretylium-control
p(x)s, S = 0.094 for 14 A < IxI < 23 A, for the
clofilium-control p(x)s, S = 0.071 for 9 A < lx < 16 A,
and for the nimodipine-control p(x)s, S = 0.136 for
9 A < Ix < 22 A. Corresponding residuals for the
swellcheck reconstruction of the same regions as that
evaluated for the drug-control p(x)s; R = 0.045 for
14A < [xl < 23A,R=0.055forA9A Ixl < 16A,and
R = 0.036 for 9 A < lx < 22 A. These regions
correspond to the headgroup/glycerol backbone region,
the acyl-chain region, and the glycerol backbone and
acyl chain region of the membrane, respectively. Each
residual or significance is the average calculated from
n > 4. In all cases, our degree of significance for the
drug-containing samples were higher than the residuals
calculated for the same regions of the control electron
density profiles.
Autocorrelation analysis
There are two unknowns in the calculation of an
absolute electron density profile, the instrumental scal-
ing factor, K, and F(O). Because our F(s) are relative, the
electron density profiles can be fit to any data set KF(s),
where K is an unknown. The effect of K on the
interpretation of electron density profiles is a scaling
factor and the effect of F(0) is a constant offset. These
two variables complicate the choice of an arbitrary
relative scale when comparing electron density profiles.
To direct the choice of K and F(0), autocorrelation
analysis of the experimental intensity functions was
performed. The APmi(x) are relatively insensitive to K,
as long as K is similar for both data sets. Given that the
beam optics, x-ray flux, sample alignment, and detector
are virtually the same from one experiment to the next,
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FIGURE 4 (a) Calculated electron density profiles for clofilium (----)
and a matched control ( ). The unit cell repeat distances are 54.5 A
and 55.0 A, respectively, at 55% r.h. and 6°C. The Ap(x) is shown
(- -), and the electron density difference centered at ± 13 A, with a
distribution ranging from 191 to 116 A, is attributed to the presence of
clofilium. a is indicated by the arrow. The p(x)s have been minimally
scaled and offset such that the Ap(x) is consistent with the autocorrela-
tion analysis. (b) Calculated electron density profiles for nimodipine
(----) and a matched control ( ). The unit cell repeat distances are
55.9 A and 56.3A, respectively, at 55% r.h. and 6°C. The Ap(x) is shown
(- -), and the electron density difference centered at + 16 A, with a
distribution ranging from 191 to 1221 A, is attributed to the presence of
nimodipine. a is indicated by the arrow. The p(x)s have been minimally
scaled and offset such that the Ap(x) is consistent with the autocorrela-
tion analysis. (c) Calculated electron density profiles for bretylium
(----) and a matched control ( ). The unit cell repeat distances are
59.0 A and 59.2 A, respectively, at 55% r.h. and 6°C. The Ap(x) is
shown (-- -), and the electron density difference centered at ± 19 A,
with a distribution ranging from 114 Al to 123 Al, is attributed to the
presence of bretylium. a and a, are indicated by the arrows. The p(x)s
have been minimally scaled and offset such that the Ap(x) is consistent
with the autocorrelation analysis.
this assumption is valid. F(O) is a function of the number
of electrons contributing to the coherent scatter; given
the ratio of lipid to drug molecules in our samples, F(O)
should vary from 0.5 to 1.7%. Because we are only
interested in the location of minima and maxima in the
APml(x), the effects of F(O) and K are minimized.
The Pml,N(x) (see Appendix), and therefore the APfl(x),
repeats at intervals of d and is centrosymmetric around
odd intervals of d/2. Consequently, the APmI(x), need
only be considered from zero to d/2. For our interpreta-
tion, we need only consider the positions of local minima
and maxima in the difference-autocorrelation function.
Assuming the "isomorphous" addition of drug to the
membrane bilayer, the positions of the minima and
maxima allows us to deduce the location of the
"isomorph" in the bilayer structure.2 This difference-
autocorrelation is to the same inherent resolution as the
electron density profiles. Scale factors and F(O) affect
the magnitudes of the minima and maxima in the
APml(x), but otherwise have little effect on its interpreta-
tion. The greater the divergence from isomorphism, the
more complicated the interpretation of the APml(x)
becomes. This is exemplified by the bretylium data set
where the need to consider a more complicated model
arises. The maxima and minima in the APmi(x) appear
shifted from the locations predicted by the p(x)s. These
shifts are predicted theoretically and will be discussed in
a future paper.
2By isomorph, we mean a single perturbation to the bilayer structure.
In our case, this includes the additional electron density contributed by
the presence of drug molecules and/or changes in the bilayer structure
caused by the presence of drug molecules.
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Fig. 5 shows two unit cells of the nimodipine-
containing and control p(x)s, with the significant autocor-
relations one observes in the calculated APml(x). These
features in the autocorrelation function arise from the
presence of the isomorph. Similar features are observed
in the case of clofilium and bretylium.
The APml(x), calculated for the clofilium versus con-
trol Pm1,N(X)s (Fig. 6 a), indicated a maximum at 8 A, a
minimum at 14 A and a second maximum at 21 A. The
maximum at 8 A corresponds to the headgroup-
isomorph autocorrelation, the minimum at 14 A corre-
sponds to the isomorph-methyl trough autocorrelation,
and the maximum at 21 A corresponds to the autocorre-
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FIGURE 5 Interpretation of the difference-autocorrelation function,
illustrated for the nimodipine data set. Two unit cells for the control
( ) and nimodipine-containing (----) BCPC bilayers are shown. The
Ap(x) is also shown (- -). The vertical lines at ± 16 A indicate the
nimodipine location in each monolayer. The arrows indicate the major
autocorrelations predicted for the APmI(x), in the range of zero to d. 13
is the distance between headgroup maxima in the unit cell, and a is the
distance between isomorph (i.e., drug) maxima in the unit cell.
(, - a)/2 is the autocorrelation between the isomorph and the
nearest headgroup. (13 + a)/2 is the autocorrelation between the
isomorph and the opposite headgroup in the unit cell. a is the
autocorrelation between isomorphs in the unit cell. a/2 is the
autocorrelation between the isomorph and the methyl-trough region
of the unit cell. Autocorrelations with the adjacent unit cell are also
predicted and are shown in the figure.
second maximum at 20 A. The interpretation of these
minima and maxima is similar to that described above
for clofilium. However, it is clear from this APmi(x) that
nimodipine more closely approximates a true isomorph
(i.e., there is a single, large difference between the
drug-containing and control bilayer structures). The
electron density increase attributed to the presence of
nimodipine would then be located at - 14 A from the
methyl-trough.
Bretylium is a special case which is not adequately
described by our simple model. Close examination of the
electron density profiles of Fig. 4 c reveals that there is a
slight shift in the headgroup position in the drug-
containing bilayer, as well as, a broadening of this
0.01
lation of the isomorph with the nearest headgroup in the
adjacent unit cell of the multibilayer (See Fig. 5 and
Appendix). There are other autocorrelations at 4 A and
d/2 which, based on model calculations, are explained
by the addition of a small perturbation to the water-
space. The electron density increase attributed to the
presence of clofilium would then be located at - 14 A
from the methyl-trough of the BCPC bilayer.
The APml(x), calculated from the nimodipine versus
control Pml,N(X)S (Figs. 5 and 6 b for interpretation),
indicated a maximum at 6 A, a minimum at 14 A and a
0.04
0.02
I
I 0.00
a
O
-0.02-
FIGURE 6 (a) The difference-autocorrelation function for the control
versus clofilium-containing BCPC bilayers. The arrows indicate the
origin of the autocorrelation (i.e., maxima and minima) in the APml(x).
The autocorrelations at 4 A and d/2 arise from a perturbation near the
water space. The a autocorrelation is predictably negligible, and not
seen (see Appendix). The interpretation of this APml(x) indicates a/2
to be approximately 14 A (i.e., the drug location is ±t 14 A from the
bilayer center). (b) The difference-autocorrelation function for the
control versus nimodipine-containing BCPC bilayers. The interpreta-
toin of these autocorrelations is shown in Fig. 5. The interpretation of
this APml(x) indicates a/2 to be approximately 14 A. (c) The difference-
autocorrelation function for the control versus bretylium-containing
BCPC bilayers. a and a, are defined in Fig. 4 c. Note that the
autocorrelation at d - (1B + al)/2 is negative due to the electron-
deficient perturbation represented by a,. The apparent maximum at
d12 arises from the overlap of the minima at a/2 and d - a/2, based on
model calculations. The interpretation of this APml(x) indicates a12 to
be -23A.
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feature. This results in a decrease in electron density
near the edge of the unit cell and an increase in electron
density adjacent to the headgroup as observed in the
Ap(x). Thus far, our working definition of an isomorph
has been a single significant perturbation in bilayer
structure between a control and drug-containing bilayer.
In the case of bretylium, there are two such perturba-
tions. Our model can be extended to accommodate two
perturbations in the bilayer structure.
The APml(x), calculated for the bretylium versus
control Pml,N(X)S, (Fig. 6 c) indicated a minimum at 10 ,
a maximum at 18 A and a second minimum at 23 A.
Given the model described above, the minimum at 10 A
arises from the autocorrelation of the electron-deficient
perturbation with the nearest headgroup in the adjacent
unit cell of the multibilayer. The maximum at 18 A then
arises from the autocorrelation of the electron-dense
perturbation with the nearest headgroup in the adjacent
unit cell. The final minimum at 23 A arises from the
autocorrelation of the electron-dense perturbation with
the methyl trough. This interpretation is consistent with
the observed APml(x) and is a reasonable interpretation
of the electron density profiles. The electron density
increase attributed to the presence of bretylium would
then be located approximately 23 A from the methyl-
trough, within the headgroup region of the bilayer
structure.
DISCUSSION
Methodological approach
We have identified the location of a typical DHP and
two Class III antiarrhythmic agents in reconstituted
bovine cardiac phosphatidylcholine membranes. The
traditional approach used in membrane diffraction to
answer similar questions is to phase the diffraction data
by swelling and to calculate electron density profiles.
These electron density profiles are then "scaled" and
''offset' relative to one another based on some physical
chemical property of the system being studied. It is
assumed that the correct scale factors and offsets are
found when some feature between profiles superim-
poses, such as the methyl trough or headgroup regions.
This can be a reasonable assumption if one, a priori, has
knowledge of some physical property of the membrane
system being studied.
The methods we introduce in this paper allow us to
ascertain the location of perturbations to bilayer struc-
tures, in this case attributed to the incorporation of drug
molecules into biological membranes. Our method is
consistent with traditional methods in that F(0) is
assumed to be zero. We introduce a scale factor in
demanding the autocorrelation function to be unity at
the origin. The effect of this normalization factor is
calculated in the Appendix and will be discussed in a
future paper. These are reasonable assumptions if we
consider the drug molecules (in the concentrations
used) to be a small perturbant. An advantage of this
approach is that the difference-autocorrelation function
is phase independent. Although this did not help much
in our case, demanding consistency between APmi(x) and
Ap(x) can be used for phase determination. Our interpre-
tation of the difference-autocorrelation functions re-
quires a predetermined knowledge that we have a
multibilayer structure and that we have the isomorphous
addition of drug molecules to this structure.
Even for a single perturbation, the analysis can be
complex (see Appendix). As we increase the number of
perturbations, the number of terms we must reconcile
increases quadratically. With this consideration in mind,
we anticipate developing a pattern-recognition ap-
proach to aid us in interpreting the difference-autocorre-
lation functions. The pattern-recognition would be based
on the relative positions, magnitudes and distributions
of the autocorrelations arising from specific perturba-
tions. The patterns would be derived from model calcu-
lations where the contribution of each feature is well
defined.
The method described in this paper allows us to
overcome some of the limitations introduced by arbi-
trary scaling and offsetting of relative electron density
profiles. We are able to determine with reasonable
certainty the location of the perturbation, and we
demand our difference-electron density profiles to be
consistent with this interpretation. We are thus able to
place our electron density profiles on relative absolute
scales.
Molecular model
To further investigate DHP interactions with biological
membranes, we have investigated the ability of Class III
antiarrhythmic agents to nonspecifically inhibit DHP-
receptor binding in cardiac sarcolemmal membranes.
The low receptor site density in cardiac sarcolemma
(McCloskey and Poo, 1986) and the high affinity of
DHPs for the membrane bilayer (Herbette et al., 1986)
makes the "membrane bilayer pathway" an attractive
hypothesis for DHP-receptor interactions. The partition-
ing of DHPs into membrane bilayers has been consid-
ered to be a nonspecific binding to a discrete level within
the anisotropic environment of the membrane bilayer,
which then potentiates drug binding to its high affinity
receptor site. A further extension of this theory is that
other amphiphilic drugs can nonspecifically inhibit DHP
binding to its receptor site by drug-drug interactions
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within the membrane, by virtue of their membrane
localization.
This study arose from the observation that two struc-
turally related drugs behave differently as inhibitors of
DHP binding to the calcium channel receptor in cardiac
membranes. In contrast to bretylium, clofilium nonspe-
cifically inhibits nimodipine binding to its receptor site
in cardiac sarcolemmal membranes. An inhibition con-
stant of Ki = 5 puM was observed for clofilium competed
against nimodipine for receptor binding (similar results
were observed with amiodarone competed against nimo-
dipine). Because clofilium can inhibit nimodipine bind-
ing but itself does not bind to the DHP high affinity
receptor site, the nonspecific interaction of clofilium
with nimodipine in the membrane bilayer appears to be
the simplest explanation. Bretylium has emerged as an
exception to many of these ligands in its partition and
binding-inhibition properties, exemplified by compari-
son to clofilium and amiodarone. Bretylium is lipid and
slightly water soluble, and would be expected to occupy
a time-averaged location near to the hydrocarbon core/
water interface. Clofilium, with its alkyl chains, would be
expected to partition deeper into the hydrocarbon core
region of the membrane bilayer, whereas amiodarone
has been shown to occupy a location deep in the
hydrocarbon core region of model membrane bilayers
(Trumbore et al., 1988). The localization of these drugs
in native membrane bilayers could then explain their
inhibition properties.
The amphiphilic DHPs appear to interact primarily
with the acyl chains of the bilayer hydrocarbon core,
exemplified by the localization of nimodipine in BCPC
bilayers. A large portion of the molecular mass of these
compounds is located below the hydrocarbon core/
water interface. The Class III antiarrhythmic amio-
darone has been shown to inhibit nimodipine binding to
sarcolemmal receptor sites (data not shown). Amio-
darone has also previously been shown to occupy a
location in the membrane bilayer spanning most of the
hydrocarbon core region, thus, overlapping the location
occupied by nimodipine. Because of the size of amio-
darone and its membrane location, its ability to inhibit
nimodipine binding could not be assigned to any specific
chemical moiety of it's structure. Presently, it has been
demonstrated that bretylium has no effect on DHP
receptor binding, whereas the structurally related Class
III antiarrhythmic clofilium has a marked effect. In the
presence of bretylium, the electron density profile struc-
tures indicate additional electron density at + 19 A from
the bilayer center in the phospholipid headgroup region
of the BCPC membrane bilayers. In the presence of
clofilium, an increase in electron density was observed
centered at + 13 A from the bilayer center. Because the
structure of these two drugs are dominated by their
halogenated-phenyl rings, the two phenyl rings occupy
different locations within the anisotropic membrane
environment. In the presence of nimodipine, an increase
in electron density was observed at + 16 A, with an
extent from 9 A to 22 A.
These results indicated that clofilium's and bretyli-
um's phenyl rings occupied different locations in BCPC
bilayers, and that these locations are enveloped by the
location of nimodipine. This may explain the inhibition
of nimodipine binding in CSL membranes. The distribu-
tion of increased electron density attributed to the
presence of nimodipine completely superimposed the
distributions of bretylium and clofilium. In addition,
neutron diffraction of selectively deuterated analogs
(2,6-methyl groups on the dihydropyridine ring) of
nimodipine demonstrated that the dihydropyridine
methyl-groups were located at the hydrocarbon core/
water interface, with the phenyl-ring moiety, more than
likely, positioned towards the center of the bilayer
(Herbette, 1985).
Reexamining the structural formulas (Fig. 1), the
charged-amine to phenyl-ring distance differs, between
bretylium, and clofilium, by three methylene segments.
Assuming the charged-amine to prefer the hydrocarbon
core/water interfacial region of the bilayer, and the
aryl-ring to prefer the hydrophobic environment of the
acyl-chain region of the bilayer, we can calculate an
estimated difference between the locations of the two
drugs based on their physical properties. We can then
directly compare this empirical calculation to the ob-
served difference-electron density profiles. Based on this
orientation, and the average length of a carbon-carbon
bond (1.54 A), the positions of the two phenyl-moieties
in the bilayer would be expected to differ by 4.6 A. The
experimentally determined difference is actually 6 A,
which is reasonably close to our calculation considering
experimental error, the fluid nature of the BCPC bilay-
ers, and the time-averaged distribution observed for
these drugs.
In light of this, the inhibition of nimodipine's binding
to its receptor by clofilium would seem to arise from the
interaction of clofilium's phenyl ring with nimodipine's
phenyl ring at the same membrane bilayer location.
Bretylium's phenyl ring would then interact at the same
membrane bilayer location of nimodipine's dihydropyri-
dine moiety. Therefore, DHP-receptor site interactions
would appear to require localization of the DHP in the
hydrocarbon chain region of the bilayer. The proposed
model is a reasonable interpretation which takes into
account all of the experimental information (Fig. 7).
Mechanistically, the nonspecific inhibition could then
originate from either (a) interference with DHP localiza-
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FIGURE 7 Molecular model. The combined diffraction and competition binding results are consistent with the schematic model illustrated above.
The nonspecific inhibition phenomenon is a steric effect of one amphiphile upon another. The halogenated-phenyl ring of bretylium is located in
the head group region of the BCPC membrane, whereas that of clofilium is located within the acyl-chain region of the bilayer. The charged amine
of both drugs is expected to remain associated with the hydrocarbon core/water interface. Nimodipine spans both of these regions, presumably
with the pyridine ring oriented such that the methyl-groups align at the hydrocarbon core/water interface (Herbette, 1985) and the phenyl ring
extends into the acyl-chain region of the BCPC bilayer. Within the limits of the "membrane bilayer pathway" proposed by Rhodes et al. (1985), the
functional location for DHP-receptor binding is that occupied by clofilium, within the bulk lipid phase (indicated by the shaded region).
tion and/or lateral diffusion preventing the specific
DHP-protein receptor site interaction, presumably initi-
ated by the phenyl-ring portion of nimodipine (a bulk
lipid bilayer effect), or (b) the phenyl ring of clofilium
could sterically inhibit the movement of the phenyl ring
of nimodipine from its location in the lipid annulus to
the calcium channel receptor site (a lipid annulus/
protein interface effect), or (c) the inhibition could
occur directly at the calcium channel receptor by the
nonspecific interaction of clofilium's phenyl ring with
the protein receptor site, thereby inhibiting the specific
binding of nimodipine (a protein receptor site effect).
The first possible mechanism is unlikely given the low
concentrations of drugs used in the binding studies. The
second mechanism is intriguing because it implies that
the receptor site includes low affinity anchoring in the
lipid annulus, with high affinity interactions confined to
the protein receptor, and that the two interactions may
be coupled. The third mechanism is analogous to the
second in that first, a low affinity anchoring of clofilium's
phenyl ring to the protein receptor site occurs, thereby
inhibiting the interaction of nimodipine's phenyl ring
with the receptor. According to this model, clofilium
does not go on to bind with high affinity to the DHP
receptor, presumably because it lacks the necessary
chemical structure of the dihydropyridine ring.
CONCLUSION
Static model
These studies are consistent with the "membrane bi-
layer pathway" for DHP-receptor binding proposed by
Rhodes et al. (1985). The results presented above
support the access of nimodipine to its receptor site, in
cardiac sarcolemmal membranes, via the acyl-chain
region of the bilayer. Because nimodipine typifies the
class of DHP calcium channel antagonists, these results
strongly support the membrane bilayer pathway as a
general mechanism of DHP-receptor interaction. The
differential ability of bretylium and clofilium to nonspe-
cifically inhibit nimodipine-receptor binding in CSL
membranes suggests that this inhibition arises from the
steric interaction of clofilium's phenyl ring with nimo-
dipine's phenyl ring in either the membrane bilayer,
lipid annulus or protein receptor site at a specific
location in the membrane bilayer. This would then
implicate the phenyl-ring portion of nimodipine as an
initiating recognition element for binding to the calcium
channel receptor site in addition to its probable role of
orienting and anchoring the DHP within the membrane
bilayer to set up a site specific interaction of nimo-
dipine's dihydropyridine ring with its receptor.
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Dynamic model
The static location information obtained from the small
angle x-ray diffraction studies has been extrapolated to
the nonspecific inhibition of DHP-receptor binding. The
time-averaged locations are representative of the rapid
partitioning and localization of the drugs in canine
cardiac sarcolemmal membranes. These locations should
then reflect the kinetic events responsible for the inhibi-
tion of nimodipine binding. The final state of equilib-
rium must be independent of the pathway. However, if
the receptor site is considered to have specific and
nonspecific components as a result of lipid and/or
protein, inhibition of the nonspecific binding component
could alter the final state of equilibrium. Alternatively,
the phenyl-ring of clofilium could sterically inhibit the
phenyl ring of nimodipine from binding at the calcium
channel receptor site.
APPENDIX
To a first approximation, we can describe the electron density profile
for the lipid bilayer by the following equation:
P1(x) =g1 *[b(-2)+ +g2 ()' (1)
where gl and g2 are Gaussian distributions centered around the origin,
i.e.,
= An exp (-iTw2x2)
with
41n2
i,2 =
(FWHM)2kK
For our model A2 < 0 < A1 and is the separation between the
headgroup regions. The methyl trough region is centered at zero. The
"*" denotes the convolution product, and "8" the Dirac delta function.
The unit cell autocorrelation, P(x), is given by
P(x) = p(x) * p(-x). (2)
If the bilayers are stacked into multibilayers, with a bilayer periodicity
of d, then the multibilayer autocorrelation, Pmi is given by
Pml(X) = P(x) + P(d - x), (3)
For 0 < x < d. Eq. 3 is sufficient to reconstruct the multilayer
autocorrelation function everywhere because the function is periodic
in d. It is also centrosymmetric around (2n + 1)d/2, where n is an
integer.
If we assume a perturbation or isomorph to be described by a
Gaussian distribution, g3, located at ±a/2 from the bilayer center, the
electron density profile for the isomorph is given by
P2(X) = Pi(X) + g3 * 8(- 2) + 8( )]. (4)
Given Eqs. 1-4, we can calculate for 0 < x < d,
APml PmI,N2(X) Pml,N1(X)
r g2 g-2 l
2g2(O) + g22(p) + 2(o) 2g2(O) + g2(0)
* [8(0) + i(d - 1)]
2g, g2 2g *g2 1
L2g2(o) + g2(o) + 2g2(o) 2gl2(o) + g2(o)
*82 [2glo(0 +2(O) + 2g3(O)1
[(1 2 ) 2 )
+ |-d - 2 ) + 93 2
[2(0) + (0) + 2g2(0)] 2 2
+[2(0) + (0) + 2g3(O)] *[8(a)+ (d-a)]. (5)
where gn = gn * gn and PmI,N(X) = Pmi(x)frq. n is a normalization
constant derived from the weighting of the b(O) term in Eq. 3. A
consequence of normalization is to remove any scaling bias in the data.
Eq. 5is valid forO0 < a < d3 < d.ForO0 < d3 < a < d, (3- a)is
replaced by (a - 1) in Eq. 5, everywhere.
The major contributions to AvPmi(X) are at (,13 + a)/2, (1 - a)/2, d -
(13 + a)/2, d - ( - a)/2, a/2 and d - a/2 (for example, see Figs. 5
and 6 b). Terms at a and d - a are small becauseg3 <mgt2 org2. 1/2,
d - 1/2, and d - arise from normalization and are predicted to be
small for the same reason.
This formalism can be extended to include multiple perturbations
and to accommodate situations where three or more Gaussians are
required to model the electron density profile of the lipid bilayer in Eq.
1. These and other considerations will be specifically addressed in a
future manuscript.
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